Our program strongly supports and encourages to do research. Our focus is on Clinical research projects. Extensive database in many of the specialty fields allows our residents to develop unique research topics.
Dr. Kevin Kelly, Dr. Thomas Scott and Dr. Carol Schramke are pleased to serve as the primary contacts and mentors for those residents seeking an extended and individualized research exposure during their training.
Senior Residents at AAN 2024
ACCEPTED Manuscripts Current & Post Graduates
1. Rahul Rahangdale, MD, Thomas F. Scott, MD, Timothy Leichliter, MD, Susan Baser, MD, and James Valeriano, MD “A Case of Paroxysmal Dystonia Associated with LGI-1 Antibody Encephalitis” Clin Neurol Neurosurg. 2019 Nov;186:105508. doi: 10.1016/j.clineuro.2019.105508. Epub 2019 Sep 3.
2. Igor B. Títoff, D.O., Victoria Títoff, D.O., Thomas F. Scott, M.D. “Is Baseline Routine Renal Ultrasound Indicated for All MS Patients?” Postgrad Med J. 2019 Oct 13. pii: postgradmedj-2019-136838. doi: 10.1136/postgradmedj-2019-136838. [Epub ahead of print]
3. Sandeep Rana, MD, FAAN, Arthur Alcantara Lima, MD, Rahul Chandra, MD, James Valeriano, MD, Troy Desai, MD, William Freiberg, DO, and George Small, MD “Novel Coronavirus (COVID-19) Associated Guillain-Barré Syndrome: Case Report” Journal of Clinical Neuromuscular Disease. 21(4):240-242, June 2020.
SUBMITTED Manuscripts
1. Bahareh Sianati, Sandeep S. Rana, Murat Sari, Jody Leonardo, and Thomas F. Scott “Autoimmune encephalitis associated with Anti-GAD 65 antibodies” Multiple Sclerosis and Related Disorders Manuscript submission
2. Tanvi Rana, Chris Hackett, Tim Quezada, Veli Bakalov, Abhishek Chaturvedi, and Sandeep Rana “Impact of the COVID-19 Pandemic on Graduate Medical Education: Resident Perspective” Journal of Graduate Medical Education
Department |
Short Title |
Indication |
2020 Study Name / Description |
---|---|---|---|
Neurology |
Orion OLE |
ALS |
Effects of oral levosimendan on respiratory function in patients with ALS |
Neurology |
Oral Edaravone |
ALS |
A phase 3 multicenter, open-label safety study of oral edaravone |
Neurology |
LRP4 |
MG |
Characterization of Argin/LRP4 Antibody Positive Myasthenia Gravis |
Neurology |
Treat-MS |
MS |
Traditional versus Early Aggressive Therapy for Multiple Sclerosis |
Neurology |
CHARM |
Stroke |
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, |
Neurology |
Core VNS |
Epilepsy |
Comprehensive Outcomes Registry in Subjects with Epilepsy Treated |
Neurology |
Immunovant |
MG |
A phase lb, multicenter, randomized, double-blind, placebo-controlled |
Neurology |
Quadrant |
Parkinson's |
Molecular and functional biomarkers of Parkinson's disease |
Neurology |
RAISE |
MG |
A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled |
Neurology |
RAISE XT |
MG |
A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled |
Neurology |
Xenon |
Epilepsy |
A Randomized, Double-blind, Placebo-Controlled, Multicenter study to |
Pulmonary Critical |
Savior II |
Covid-19 |
A Prospective, Randomized, Controlled Study Assessing Vagus Nerve |
Neurology |
Combat - ALS |
ALS |
A phase 2B/3, Multi-center, Randomized, Double Blind Placebo- |
Neurology |
Migraine - MOH |
Migraine |
A Phase 4, randomized, Double-blind, Placebo-controlled and safety of |
National presentations almost every year by our residents at: